全文获取类型
收费全文 | 993篇 |
免费 | 56篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 49篇 |
妇产科学 | 7篇 |
基础医学 | 73篇 |
口腔科学 | 53篇 |
临床医学 | 70篇 |
内科学 | 138篇 |
皮肤病学 | 27篇 |
神经病学 | 18篇 |
特种医学 | 221篇 |
外科学 | 37篇 |
综合类 | 34篇 |
预防医学 | 41篇 |
眼科学 | 4篇 |
药学 | 41篇 |
肿瘤学 | 257篇 |
出版年
2023年 | 4篇 |
2021年 | 7篇 |
2019年 | 6篇 |
2018年 | 16篇 |
2017年 | 12篇 |
2016年 | 10篇 |
2015年 | 13篇 |
2014年 | 18篇 |
2013年 | 18篇 |
2012年 | 21篇 |
2011年 | 22篇 |
2010年 | 27篇 |
2009年 | 36篇 |
2008年 | 33篇 |
2007年 | 26篇 |
2006年 | 25篇 |
2005年 | 22篇 |
2004年 | 24篇 |
2003年 | 23篇 |
2002年 | 18篇 |
2001年 | 27篇 |
2000年 | 13篇 |
1999年 | 25篇 |
1998年 | 43篇 |
1997年 | 45篇 |
1996年 | 42篇 |
1995年 | 35篇 |
1994年 | 25篇 |
1993年 | 31篇 |
1992年 | 23篇 |
1991年 | 21篇 |
1990年 | 18篇 |
1989年 | 34篇 |
1988年 | 30篇 |
1987年 | 49篇 |
1986年 | 27篇 |
1985年 | 18篇 |
1984年 | 13篇 |
1983年 | 13篇 |
1982年 | 15篇 |
1981年 | 20篇 |
1980年 | 17篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 21篇 |
1975年 | 10篇 |
1934年 | 4篇 |
1927年 | 4篇 |
1926年 | 4篇 |
排序方式: 共有1071条查询结果,搜索用时 15 毫秒
11.
12.
13.
Sequence comparison of human and yeast telomeres identifies structurally distinct subtelomeric domains 总被引:6,自引:2,他引:6
Flint J; Bates GP; Clark K; Dorman A; Willingham D; Roe BA; Micklem G; Higgs DR; Louis EJ 《Human molecular genetics》1997,6(8):1305-1313
We have sequenced and compared DNA from the ends of three human
chromosomes: 4p, 16p and 22q. In all cases the pro-terminal regions are
subdivided by degenerate (TTAGGG)n repeats into distal and proximal sub-
domains with entirely different patterns of homology to other chromosome
ends. The distal regions contain numerous, short (<2 kb) segments of
interrupted homology to many other human telomeric regions. The proximal
regions show much longer (approximately 10-40 kb) uninterrupted homology to
a few chromosome ends. A comparison of all yeast subtelomeric regions
indicates that they too are subdivided by degenerate TTAGGG repeats into
distal and proximal sub-domains with similarly different patterns of
identity to other non-homologous chromosome ends. Sequence comparisons
indicate that the distal and proximal sub-domains do not interact with each
other and that they interact quite differently with the corresponding
regions on other, non- homologous, chromosomes. These findings suggest that
the degenerate TTAGGG repeats identify a previously unrecognized,
evolutionarily conserved boundary between remarkably different subtelomeric
domains.
相似文献
14.
ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome 总被引:11,自引:3,他引:11
Picketts DJ; Higgs DR; Bachoo S; Blake DJ; Quarrell OW; Gibbons RJ 《Human molecular genetics》1996,5(12):1899-1907
It was shown recently that mutations of the ATRX gene give rise to a
severe, X-linked form of syndromal mental retardation associated with alpha
thalassaemia (ATR-X syndrome). In this study, we have characterised the
full-length cDNA and predicted structure of the ATRX protein. Comparative
analysis shows that it is an entirely new member of the SNF2 subgroup of a
superfamily of proteins with similar ATPase and helicase domains. ATRX
probably acts as a regulator of gene expression. Definition of its genomic
structure enabled us to identify four novel splicing defects by screening
52 affected individuals. Correlation between these and previously
identified mutations with variations in the ATR-X phenotype provides
insights into the pathophysiology of this disease and the normal role of
the ATRX protein in vivo.
相似文献
15.
16.
17.
18.
Glenn Liu David R Gandara Primo N Lara Derek Raghavan James H Doroshow Przemyslaw Twardowski Philip Kantoff William Oh KyungMann Kim George Wilding 《Clinical cancer research》2004,10(3):924-928
PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor with preclinical activity against prostate cancer cell lines. A Phase II trial was conducted to determine the activity of flavopiridol in patients with metastatic hormone-refractory prostate cancer. EXPERIMENTAL DESIGN: A total of 36 patients was enrolled from several institutions and treated with a 72-h continuous infusion of flavopiridol every 14 days at the eventual starting dose of 40 mg/m(2)/day. Dose escalation up to 60 mg/m(2)/day was permitted if no significant toxicity was observed. Responses were assessed every 12 weeks. Only those patients completing four courses of the 72-h infusion were considered evaluable for response because the primary objective was to determine progression-free survival at 6 months given the cytostatic nature of the agent. RESULTS: This study was conducted in a two-stage fashion. During the first stage, at least 20 evaluable patients needed to be enrolled to assess response. There were 22 of 36 patients evaluable for response. No objective responses were observed. Only 4 patients had stable disease for 16, 26, 29, and 48 weeks, respectively, stopping the trial by design as only 3 of 22 (14%) of the patients met the 6-month progression-free survival end point. The most common toxicities were diarrhea (grade 1 and 2) and nausea, although some grade 3 and 4 diarrhea (11 and 6%, respectively) were evident. CONCLUSIONS: Flavopiridol has disappointing single-agent activity in hormone-refractory prostate cancer when administered at this dose and schedule. Its use in prostate cancer should be reserved for evaluation in combination therapies or alternative schedules. 相似文献
19.
Primo N Lara Paul Frankel Philip C Mack Paul H Gumerlock Irina Galvin Cynthia L Martel Jeff Longmate James H Doroshow Heinz Josef Lenz Derick H M Lau David R Gandara 《Clinical cancer research》2003,9(12):4356-4362
PURPOSE: Tumor hypoxia confers chemotherapy resistance. Tirapazamine is a cytotoxin that selectively targets hypoxic cells and has supra-additive toxicity with platinums and taxanes in preclinical studies. We conducted a Phase I study of tirapazamine, carboplatin, and paclitaxel and assessed potential plasma markers of hypoxia as surrogates for response. EXPERIMENTAL DESIGN: Forty-two patients with advanced solid tumors were treated at four dose levels; parallel dose escalations were carried out in chemotherapy-naive and previously treated subjects. Pre and post-therapy plasma levels of the hypoxia-induced proteins plasminogen activator inhibitor-1 and vascular endothelial growth factor were measured. RESULTS: Three of four chemotherapy-na?ve patients developed dose-limiting toxicities at dose level 4 (grade 3 stomatitis/infection, grade 3 emesis, and grade 4 febrile neutropenia). Four of seven previously treated patients developed dose-limiting toxicities at dose level 3, including one death [grade 3 myalgia, grade 3 infection/grade 4 neutropenia, grade 3 infection/grade 4 neutropenia, and grade 5 infection (death)/grade 4 neutropenia]. Of 38 patients assessable for response, 3 had a complete response, 1 a partial response, 1 an unconfirmed partial response, and 23 had stable disease in at least one evaluation; 10 quickly progressed. One complete responder had normalization of vascular endothelial growth factor and plasminogen activator inhibitor-1 levels. CONCLUSION: Dose levels 3 (carboplatin AUC of 6, 225 mg/m(2) paclitaxel, and 330 mg/m(2) tirapazamine) and 2 (carboplatin AUC 6, 225 mg/m(2) paclitaxel, and 260 mg/m(2) tirapazamine) are the maximum tolerated doses for chemotherapy naive and patients treated previously, respectively. Dose level 3 is the experimental arm of a Phase III Southwest Oncology Group trial (S0003) in advanced non-small cell lung cancer. Potential markers of tumor hypoxia may be useful correlates in studies of hypoxic cytotoxins and are being prospectively investigated in S0003. 相似文献
20.
D. R. Gandara Martin J. Edelman John J. Crowley Derick H. M. Lau Robert B. Livingston 《Cancer chemotherapy and pharmacology》1997,41(1):75-78
Background: Edatrexate and carboplatin are each active single agents in the treatment of non-small-cell lung cancer (NSCLC). Preclinical
studies in NSCLC lines have demonstrated schedule-dependent synergy of edatrexate followed by carboplatin. In a phase I trial,
we demonstrated the tolerability of this combination, the ability of ice-chip cryotherapy to ameliorate dose-limiting mucositis,
and promising activity in NSCLC. This phase II trial (SWOG 9207) was undertaken to investigate the efficacy of this regimen
in stage IV NSCLC. Methods: A total of 24 patients with stage IV disease were accrued to this Southwest Oncology Group (SWOG) multicenter study. Treatment
consisted of edatrexate 80 mg/m2 (50% dose on day 8) intravenously weekly for 5 weeks, then every other week, and carboplatin 350 mg/m2 every 28 days. Results: Of the 24 patients, 23 were assessable for toxicity and response; one was ineligible for study entry. Myelosuppression was
the most significant toxicity; grade 3–4 neutropenia was seen in 8/23 patients. Two patients died of neutropenic sepsis during
the first cycle of therapy, in both instances associated with the presence of pleural effusions. Although mild mucositis was
common, it was dose-limiting (grade 3) in only three patients. Objective response was observed in 3/23 patients (13%). The
median survival time was 7 months, and 30% of patients remained alive at one year. Conclusions: This study suggests that ice-chip cryotherapy is effective in reducing the severity of mucositis typically associated with
this edatrexate schedule of administration. However, unexpectedly severe myelosuppression resulted in death from neutropenic
sepsis in two patients with third space fluid collections, leading to a protocol amendment to exclude such patients from study
entry. Furthermore, response and median survival with this dose schedule of edatrexate and carboplatin do not appear to be
improved compared to other chemotherapeutic regimens tested by SWOG in this patient population.
Received: 12 August 1996 / Accepted: 8 May 1997 相似文献